EA202091617A1 - HETEROARYL-SUBSTITUTED PYRROLO [2,3-B] PYRIDINES AND PYRROLO [2,3-B] PYRIMIDINES AS INHIBITORS OF JANUS KINASE - Google Patents

HETEROARYL-SUBSTITUTED PYRROLO [2,3-B] PYRIDINES AND PYRROLO [2,3-B] PYRIMIDINES AS INHIBITORS OF JANUS KINASE

Info

Publication number
EA202091617A1
EA202091617A1 EA202091617A EA202091617A EA202091617A1 EA 202091617 A1 EA202091617 A1 EA 202091617A1 EA 202091617 A EA202091617 A EA 202091617A EA 202091617 A EA202091617 A EA 202091617A EA 202091617 A1 EA202091617 A1 EA 202091617A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrrolo
heteroaryl
janus kinase
pyridines
pyrimidines
Prior art date
Application number
EA202091617A
Other languages
Russian (ru)
Inventor
Джеймс Д. Роджерс
Стейси Шепард
Томас П. Мадускуи
Хайшэн Ван
Нику Фалахатпишех
Мария Рафальски
Аргириос Г. Арванитис
Льюис Сторейс
Рави Кумар Джаллури
Джордан С. Фридман
Кришна Вадди
Original Assignee
Инсайт Холдингс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инсайт Холдингс Корпорейшн filed Critical Инсайт Холдингс Корпорейшн
Publication of EA202091617A1 publication Critical patent/EA202091617A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Настоящее изобретение относится к гетероарилзамещенным пирроло[2,3-b]пиридинам (I) и гетероарилзамещенным пирроло[2,3-b]пиримидинам, которые модулируют активность Янус-киназы и могут использоваться для лечения заболеваний, связанных с активностью Янус-киназы, включая, например, иммунносвязанные заболевания, заболевания кожи, миелоидные пролиферативные заболевания, рак и другие заболевания.The present invention relates to heteroaryl-substituted pyrrolo [2,3-b] pyridines (I) and heteroaryl-substituted pyrrolo [2,3-b] pyrimidines, which modulate Janus kinase activity and can be used to treat diseases associated with Janus kinase activity, including for example, immune related diseases, skin diseases, myeloid proliferative diseases, cancer and other diseases.

EA202091617A 2006-11-16 2006-12-12 HETEROARYL-SUBSTITUTED PYRROLO [2,3-B] PYRIDINES AND PYRROLO [2,3-B] PYRIMIDINES AS INHIBITORS OF JANUS KINASE EA202091617A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85940406P 2006-11-16 2006-11-16

Publications (1)

Publication Number Publication Date
EA202091617A1 true EA202091617A1 (en) 2020-10-30

Family

ID=73129268

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202091617A EA202091617A1 (en) 2006-11-16 2006-12-12 HETEROARYL-SUBSTITUTED PYRROLO [2,3-B] PYRIDINES AND PYRROLO [2,3-B] PYRIMIDINES AS INHIBITORS OF JANUS KINASE
EA202091616A EA202091616A3 (en) 2006-11-16 2006-12-12 HETEROARYL-SUBSTITUTED PYRROLO [2,3-B] PYRIDINES AND PYRROLO [2,3-B] PYRIMIDINES AS INHIBITORS OF JANUS KINASE

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202091616A EA202091616A3 (en) 2006-11-16 2006-12-12 HETEROARYL-SUBSTITUTED PYRROLO [2,3-B] PYRIDINES AND PYRROLO [2,3-B] PYRIMIDINES AS INHIBITORS OF JANUS KINASE

Country Status (1)

Country Link
EA (2) EA202091617A1 (en)

Also Published As

Publication number Publication date
EA202091616A2 (en) 2020-10-30
EA202091616A3 (en) 2021-01-29

Similar Documents

Publication Publication Date Title
EA201691294A2 (en) Heteroaryl-substituted Pyrrolo [2,3-b] pyridine and pyrrolo [2,3-b] Pyrimidine as JANUS-KINASE INHIBITORS
EA201070618A1 (en) 4-PYRAZOLYL-N-Arylpyrimidine-2-amines and 4-pyrazoyl-N-heteroarylpyrimidine-2-amines as an Inhibitor of Kinase JANUS
MX2009012623A (en) Heterocyclic kinase modulators.
MX2009006162A (en) Pyrrolo [2, 3-b] pyridine derivatives as kinase modulators.
PH12014501355B1 (en) Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors
TN2009000142A1 (en) Bicyclic triazoles as protein kinase modulators
TW200833692A (en) Triazolopyridazine protein kinase modulators
UA95244C2 (en) Compounds and methods for kinase modulation, and indications therefor
EA201070013A1 (en) SALTS of the JANUS-KINASE INHIBITOR (R) -3- (4- (7H-PYRROLO [2,3-d] PYRIMIDIN-4-IL) -1H-PYRAZOL-1-IL) -3-CYCLOPENTYL-PROPHANNITRY
EA201391682A1 (en) SUBSTITUTED DERIVATIVES OF INDAZOLS ACTIVE AS KINASE INHIBITORS
EA201290878A1 (en) IMIDAZO [1,2-a] DERIVATIVES AND THEIR APPLICATION FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS
HK1139941A1 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
MX2012012031A (en) Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders.
EA202091617A1 (en) HETEROARYL-SUBSTITUTED PYRROLO [2,3-B] PYRIDINES AND PYRROLO [2,3-B] PYRIMIDINES AS INHIBITORS OF JANUS KINASE
UA106617C2 (en) N- (hetero) arylpyrrolidine derivatives of pirazol-4-ylpyrrolo [2,3-d] pyrimidines and pyrrol-3-ylpyrrolo [2,3-d] pyrimidines as inhibitors